UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 59

Sortiert nach

Phase 1 study of ceritinib in pediatric patients with malignancies harboring activated anaplastic lymphoma kinase (ALK): Safety, pharmacokinetics and efficacy results from the fed population

European journal of cancer (1990), 2016-12, Vol.69, p.S49-S50

2016

Volltextzugriff (PDF)

Management of cerebral azole-resistant Aspergillus fumigatus infection: A role for intraventricular liposomal-amphotericin B

Journal of global antimicrobial resistance., 2020-09, Vol.22, p.354-357

2020

Volltextzugriff (PDF)

Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia

Blood, 1998-03, Vol.91 (6), p.2092-2098

1998

Volltextzugriff (PDF)

The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia

Leukemia, 2011-08, Vol.25 (8), p.1239-1248

2011

Volltextzugriff (PDF)

The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells

Leukemia, 2012-02, Vol.26 (2), p.255-264

2012

Volltextzugriff (PDF)

Novel therapies for children with acute myeloid leukaemia

Leukemia, 2013-07, Vol.27 (7), p.1451-1460

2013

Volltextzugriff (PDF)

Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations

Leukemia, 2012-10, Vol.26 (10), p.2204-2211

2012

Volltextzugriff (PDF)

Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target

Leukemia, 2013-03, Vol.27 (3), p.560-568

2013

Volltextzugriff (PDF)

Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML―BFM and DCOG study groups

Leukemia, 2011-11, Vol.25 (11), p.1704-1710

2011

Volltextzugriff (PDF)

136P Efficacy and safety of larotrectinib (laro) as first-line treatment for paediatric (paed) patients (pts) with TRK fusion cancer

ESMO open, 2024-03, Vol.9, p.102525, Article 102525

2024

Volltextzugriff (PDF)

3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients

European journal of cancer (1990), 2018-02, Vol.90, p.102-110

2018

Volltextzugriff (PDF)

Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML

Leukemia, 2009-02, Vol.23 (2), p.262-270

2009

Volltextzugriff (PDF)

Gene expression profiling in MDS and AML: potential and future avenues

Leukemia, 2011-06, Vol.25 (6), p.909-920

2011

Volltextzugriff (PDF)

Telomere length and telomerase complex mutations in pediatric acute myeloid leukemia

Leukemia, 2013-08, Vol.27 (8), p.1786-1789

2013

Volltextzugriff (PDF)

EphB1 Suppression in Acute Myelogenous Leukemia: Regulating the DNA Damage Control System

Molecular cancer research, 2015-06, Vol.13 (6), p.982-992

2015

Volltextzugriff (PDF)

Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery

Journal of thrombosis and haemostasis, 2018-11, Vol.16 (11), p.2196-2207

2018

Volltextzugriff (PDF)

P079 BRAF mutations in juvenile myelomonocytic leukemia

Leukemia research, 2007, Vol.31, p.S83-S83

2007

Volltextzugriff (PDF)

Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study

Leukemia, 2009-08, Vol.23 (8), p.1472-1479

2009

Volltextzugriff (PDF)

The clinical relevance of minor paroxysmal nocturnal hemoglobinuria clones in refractory cytopenia of childhood: a prospective study by EWOG-MDS

Leukemia, 2014-01, Vol.28 (1), p.189-192

2014

Volltextzugriff (PDF)

Low frequency of DNMT3A mutations in pediatric AML, and the identification of the OCI-AML3 cell line as an in vitro model

Leukemia, 2012-02, Vol.26 (2), p.371-373

2012

Volltextzugriff (PDF)

133 - Phase 1 study of ceritinib in pediatric patients with malignancies harboring activated anaplastic lymphoma kinase (ALK): Safety, pharmacokinetics and efficacy results from the fed population

European journal of cancer (1990), 2016-12, Vol.69, p.S49-S50

2016

Volltextzugriff (PDF)

Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML

Leukemia, 2008-07, Vol.22 (7), p.1428-1430

2008

Volltextzugriff (PDF)

PF416 GROWTH RATE AND ENDOCRINE EFFECTS OF DASATINIB THERAPY OBSERVED IN A RETROSPECTIVE ANALYSIS OF A PHASE 2 CLINICAL TRIAL FOR PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML‐CP)

HemaSphere, 2019-06, Vol.3 (S1), p.161-n/a

2019

Volltextzugriff (PDF)

TET2 mutations in childhood leukemia

Leukemia, 2011-01, Vol.25 (1), p.189-192

2011

Volltextzugriff (PDF)

1 – 25 von 59

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(58)
Mit Volltextzugriff
(56)

Publikationsform

Artikel
(59)

Sprache

Englisch
(59)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(48)
Science & Technology
(48)
Humans
(36)
Hematology
(33)
Oncology
(33)
Child
(28)
Leukemia
(21)
Pediatrics
(21)
Female
(20)
Child, Preschool
(18)
Male
(17)
Biological And Medical Sciences
(16)
Medical Sciences
(16)
Adolescent
(15)
Acute Myeloid Leukemia
(14)
Genetic Aspects
(14)
Hematologic And Hematopoietic Diseases
(14)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(14)
Mutation
(14)
Patients
(14)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase 1 study of ceritinib in pediatric patients with malignancies harboring activated anaplastic lymphoma kinase (ALK): Safety, pharmacokinetics and efficacy results from the fed population

Management of cerebral azole-resistant Aspergillus fumigatus infection: A role for intraventricular liposomal-amphotericin B

Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia

The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia

The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells

Novel therapies for children with acute myeloid leukaemia

Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations

Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target

Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML―BFM and DCOG study groups

136P Efficacy and safety of larotrectinib (laro) as first-line treatment for paediatric (paed) patients (pts) with TRK fusion cancer

3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients

Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML

Gene expression profiling in MDS and AML: potential and future avenues

Telomere length and telomerase complex mutations in pediatric acute myeloid leukemia

One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P®/Humate P® treatment in von Willebrand disease patients

EphB1 Suppression in Acute Myelogenous Leukemia: Regulating the DNA Damage Control System

Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery

P079 BRAF mutations in juvenile myelomonocytic leukemia

Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study

The clinical relevance of minor paroxysmal nocturnal hemoglobinuria clones in refractory cytopenia of childhood: a prospective study by EWOG-MDS

Low frequency of DNMT3A mutations in pediatric AML, and the identification of the OCI-AML3 cell line as an in vitro model

133 - Phase 1 study of ceritinib in pediatric patients with malignancies harboring activated anaplastic lymphoma kinase (ALK): Safety, pharmacokinetics and efficacy results from the fed population

Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML

PF416 GROWTH RATE AND ENDOCRINE EFFECTS OF DASATINIB THERAPY OBSERVED IN A RETROSPECTIVE ANALYSIS OF A PHASE 2 CLINICAL TRIAL FOR PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML‐CP)

TET2 mutations in childhood leukemia

Suchergebnisse filtern